

ANALYSIS OF IBRUTINIB DOSE REDUCTION IN PATIENTS DIAGNOSED WITH CHRONIC LYMPHOCYTIC LEUKAEMIA: ARE WE DOING IT RIGHT?

4CPS-190

Boo Rodríguez J, Ros Olaso A, Beristain Aramendi I, Eceiza Diez A, Latasa Berasategui A, Saíz Martínez C, García de Andoin Barandiaran MJ, Landa Alberdi J, García Echeverría D, Lizeaga Cundín G

Servicio de Farmacia. Hospital Universitario Donostia (HUD). Osakidetza



IMPORTANCE OF THE STUDY

The usual oral dosage of ibrutinib in chronic lymphatic leukemia (CLL) is 420 mg every 24h. However, comorbidities, adverse effects and drug interactions require a dose reduction (DR), and the efficacy of treatment may be compromised.

OBJECTIVE

Analyze the reasons of ibrutinib DR and its consequences on disease progression/death.

MATERIAL AND METHODS

Retrospective observational study that includes patients diagnosed with CLL treated with ibrutinib between 09/16/2020-09/16/2022 and not involved in a clinical trial.

The data was obtained from the electronic medical record (Osabide Global) and the electronic prescription program (Onkobide).


Data collection

- Demographics (sex and age)
- DR requirements and date
- Disease progression (Y/N) and date
- Death (Y/N) and date
- Treatment suspensions and date

Data calculated


- Percentage patients required DR and reasons, death and progression
- Overall median treatment duration (OMD)
- Overall median treatment duration after DR (DAMD)

RESULTS




Median age: 72,9 (53-89)
OMD: 17 months (0-73)
DAMD: 12 months (0-70)


Patients N=60




Deaths N=11



Disease progression N=4



DR requirements



CONCLUSIONS AND RELEVANCE

- The ibrutinib DR does not influence the disease progression or mortality, although the sample size is not enough for a formal statistical analysis.
- Toxicity was identified as the most common reason for DR.
- The OMD and DAMD data presented in this work are lower than those commonly published in the literature due to the technical limitations on the software systems.